No Data
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $20
Evolus to Participate in Stifel 2024 Healthcare Conference
Evolus Analyst Ratings
Earnings Preview: Evolus to Report Financial Results Post-market on November 06
$Evolus(EOLS.US)$ is scheduled to release its financial results post-market on November 06 ET. Earnings PreviewAnalysts estimate $Evolus(EOLS.US)$ to post revenue of USD63.40M for 2024Q3, up 26.76%
Express News | Evolus: On Track for U.S. Approval & Launch of Evolysse Injectable Ha Gels Beginning in 2025
Express News | Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
No Data
No Data